Anakinra in the Management of COVID-19 Infection

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

March 1, 2021

Study Completion Date

April 30, 2021

Conditions
Covid19PneumoniaCytokine Release SyndromeCorona Virus InfectionViral Infection
Interventions
DRUG

Anakinra

Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care

OTHER

Standard of Care

Patients will receive the Standard of Care therapy as per the local treatment protocol

Trial Locations (1)

Unknown

Hamad Medical Corporation, Doha

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY